Article Text

Download PDFPDF

Long-term in vivo expression of trastuzumab following intramuscular electrotransfer of the encoding DNA in mice
  1. Kevin Hollevoet1,
  2. Nick Geukens2,
  3. Greetje Vande Velde3 and
  4. Paul Declerck1
  1. Aff1 grid.5596.f0000000106687884Laboratory for Therapeutic and Diagnostic AntibodiesKU Leuven - Leuven University Leuven Belgium
  2. Aff2 grid.5596.f0000000106687884PharmAbsthe KU Leuven Antibody Center - Leuven University Leuven Belgium
  3. Aff3 grid.5596.f0000000106687884Molecular Small Animal Imaging CenterKU Leuven - Leuven University Leuven Belgium

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Meeting abstracts

In vivo antibody expression is at crossroads between monoclonal antibody (mAb) and gene therapy. Following a single intramuscular injection of the DNA that encodes a therapeutic mAb, the muscle is turned into a ‘bioreactor’, resulting in prolonged mAb secretion in circulation [13]. This innovative approach addresses several challenges associated with conventional mAb proteins. In R&D, in vivo mAb expression allows production and evaluation of leads directly into animal models. In the clinic, it can improve treatment efficacy and patient comfort by avoiding repeated high-dose injections, and provide a cost-effective answer to the increasing need for mAb combination therapies - in the field of cancer immunotherapy and beyond. This study outlines the development and delivery of a trastuzumab-encoding plasmid for in vivo mAb expression. To improve intramuscular DNA delivery in mice, we first established an optimal electrotransfer protocol using novel reporter plasmids. Following the optimized intramuscular electrotransfer of the trastuzumab-encoding plasmid, trastuzumab was detected with a commercial ELISA at therapeutically relevant concentrations (1-15 µg/ml) in the sera of athymic nude mice (n=16) for the full duration of the ongoing follow-up (>3 months). A cell viability assay demonstrated similar activity of the expressed versus commercial trastuzumab in the BT-4747 breast cancer cell line. In conclusion, we achieved proof of concept for the long-term in vivo expression of biologically active trastuzumab in mice. Ongoing work focuses on optimizing in vivo mAb expression for clinical application and evaluation for combination therapy.


  1. 1.
  2. 2.
  3. 3.